No Data
East Asia Pharmaceutical: East Asia Pharmaceutical Third Quarter Report 2024
East Asia Pharmaceutical Third Quarter Report 2024
zhejiang east-asia pharmaceutical (605177.SH): the net income in the first three quarters was 45.1692 million yuan, a decrease of 47.21% year-on-year.
Gelonghui October 30th | zhejiang east-asia pharmaceutical (605177.SH) announced that in the first three quarters of 2024, it achieved revenue of 0.963 billion yuan, a decrease of 4.13% year-on-year; the net income attributable to shareholders of the listed company was 45.1692 million yuan, a decrease of 47.21% year-on-year, with basic earnings per share of 0.40 yuan.
zhejiang east-asia pharmaceutical (605177.SH): intends to appoint Chi Zhengming as a strategic and development consultant.
Gelonghui October 11th | zhejiang east-asia pharmaceutical (605177.SH) announced that, according to the company's global strategy development, industrial layout needs, the company intends to appoint Mr. Chi Zhengming as a strategic and development consultant, to provide consulting services for the company's overall development goals, development strategy, operation strategy activities, and sign a "Strategic and Development Consultant Agreement" with Mr. Chi Zhengming, with a term of three years, from October 11, 2024 to October 10, 2027. The annual compensation for the strategic and development consultant is 1.3 million yuan (including tax). Mr. Chi Zhengming is a shareholder of the company, the actual controlling shareholder, holding more than 5% of the company's shares, and
Insiders Were the Biggest Winners as Zhejiang East Asia Pharmaceutical Co., Ltd.'s (SHSE:605177) Market Cap Grew by CN¥370m Last Week
East Asia Pharmaceutical 2024 Semi-Annual Report
Zhejiang East Asia Pharmaceutical Co., Ltd. (SHSE:605177) Might Not Be As Mispriced As It Looks After Plunging 31%No Data
No Data
